Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET
PSTVHOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, January 22, 2026 before the market open. Plus Therapeutics’ management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details.
Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
PSTV(NASDAQ:PSTV) HOUSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it will participate in the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel.
Ascendiant Capital Maintains Buy on Plus Therapeutics, Raises Price Target to $20.5
PSTVPlus Therapeutics Q1 EPS $(1.19) Misses $(0.25) Estimate, Sales $1.06M Miss $1.48M Estimate
PSTVPlus Therapeutics Receives Nasdaq Delinquency Notice Over Late Form 10-Q Submission
PSTVReported May 19, 2025: Plus Therapeutics Receives Letter Of Non-Compliance From Nasdaq
PSTVPlus Therapeutics: REYOBIQ Shows Clinical Benefit And Safety In ReSPECT-LM Clinical Trial For Patients With Leptomeningeal Metastases
PSTVD. Boral Capital Downgrades Plus Therapeutics to Hold
PSTVAscendiant Capital Maintains Buy on Plus Therapeutics, Raises Price Target to $20
PSTVPlus Therapeutics Announces Online Availability Of Abstract Titled 'Rhenium Obisbemeda (REYOBIQ) in Leptomeningeal Metastases' For Presentation And Poster To Be Presented At Nuclear Medicine And Neurooncology To Be Held May 9-10
PSTVHC Wainwright & Co. Maintains Buy on Plus Therapeutics, Lowers Price Target to $5.5
PSTVD. Boral Capital Maintains Buy on Plus Therapeutics, Maintains $9 Price Target
PSTVPlus Therapeutics FY24 EPS $(1.95) Vs. $(4.24) YoY, Grant Revenue $5.8M Up From $4.9M YoY
PSTVA Peek at Plus Therapeutics's Future Earnings
PSTVD. Boral Capital Maintains Buy on Plus Therapeutics, Maintains $9 Price Target
PSTVWhy Plus Therapeutics (PSTV) Shares Are Exploding Higher
PSTVPlus Therapeutics shares are trading higher by 183% during Thursday's session. The company announced that the FDA accepted the name REYOBIQ for the company's lead asset.
Plus Therapeutics Shares Resume Trade
PSTVPlus Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 199.4%
PSTVPlus Therapeutics Announces FDA Accepted The Name REYOBIQ For Co.'s Lead Asset
PSTVD. Boral Capital Initiates Coverage On Plus Therapeutics with Buy Rating, Announces Price Target of $9
PSTVPlus Therapeutics Regains Nasdaq Compliance, Keeps Stock Listed on Capital Market
PSTVPlus Therapeutics Continues Rally On Friday - Here's Why
PSTVPlus Therapeutics stock rises after peer-reviewed publication of Phase 1 glioma data and FDA Orphan Drug Designation for lung cancer treatment.
Plus Therapeutics Reports Peer-Reviewed Publication Of Phase 1 Glioma Data; Rhenium (186Re) Obisbemeda Shows Safety, Response And Potential Efficacy For Glioblastoma Patients
PSTVPlus Therapeutics Shares Resume Trade Following Circuit Breaker Halt
PSTVPlus Therapeutics Granted FDA Orphan Drug Designation for For Rhenium Obisbemeda In Leptomeningeal Metastases In Patients with Lung Cancer
PSTVPlus Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down -43.9%
PSTVPlus Therapeutics Secures Private Placement Of ~$15M In Gross Proceeds; Offering Price Per Common Unit Is $0.66
PSTVPlus Therapeutics Granted FDA Orphan Designation For BMEDA-Chelated Rhenium-186 Nanoliposomes For The Treatment Of Lung Cancer With Leptomeningeal Metastases
PSTVPlus Therapeutics Completes ReSPECT-LM Phase 1 Trial, Identifies Recommended Phase 2 Dose For CNS Cancer Treatment
PSTVPlus Therapeutics Closes Private Placement Of Up To $3.7M And Receives $2M Advance Payment To Support Leptomeningeal Metastases Program
PSTVHC Wainwright & Co. Reiterates Buy on Plus Therapeutics, Maintains $8 Price Target
PSTVPlus Therapeutics Q3 EPS $(0.37) Beats $(0.56) Estimate, Sales $1.46M Beat $1.14M Estimate
PSTVPlus Therapeutics And SpectronRx Announced The Signing Of A Manufacturing Services Agreement For The Production Of Rhenium (186Re) Obisbemeda, An Innovative Radiotherapy For CNS Cancers, Including Leptomeningeal Metastases And Recurrent Glioblastoma
PSTVPlus Therapeutics Presents Phase 1 Data From ReSPECT-GBM Clinical Trial At The European Society For Medical Oncology Congress 2022
PSTVPLUS THERAPEUTICS Says Entered Equity Distribution Agreement Under Which Co. May Issue, Sell Shares Of Common Stock Up To $5M
PSTV